69
Dr. Paula L. Blanco Dr. Paula L. Blanco [email protected] [email protected] Pathology in Diabetes Pathology in Diabetes October October 2015 2015

Dr. Paula L. Blanco [email protected] Pathology in Diabetes October 2015

Embed Size (px)

Citation preview

Page 1: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Dr. Paula L. BlancoDr. Paula L. [email protected]@toh.on.ca

Pathology in DiabetesPathology in Diabetes

October 2015October 2015

Page 2: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Disclosure

• You may only access and use this PowerPoint presentation for educational purposes.

• You may not post this presentation online or distribute it without the permission of the author.

Page 3: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Objectives• 3711-2 Describe the pathological changes in the pancreas for type I / II diabetes.

• 4619 Understand and recognize the pancreatic pathology in type I diabetes.

• 4620 List, understand and recognize the pathology of the major complications of diabetes: - Microvascular changes general aspects- Microvascular effects in retina- Microvascular changes in nerves- Renal pathology- Atherosclerosis in Diabetes

• 4621 Describe the special aspects of pathology of infection in diabetes.

Page 4: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Islet of Langerhans

Page 5: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

The endocrine pancreas

Pathologic basis of disease – Robbins 8th

α cells: glucagonβ cells: insulin

Page 6: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Increased synthesis and reduced degradation of glycogen, lipids and proteinsPathologic basis of disease – Robbins 8th

Insulin: most potent anabolic hormone

Hyperglycemia

Page 7: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Definition

• Diabetes is not a single disease entity but a

group of metabolic disorders sharing the

common underlying feature of hyperglycemia

Page 8: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Classification• Type I Diabetes 5-10%

• Type II Diabetes 90-95%

• Genetic defects of β cell function• Maturity-onset diabetes of the young (MODY), Neonatal diabetes

• Genetic defects in insulin action

• Exocrine pancreatic defects• Chronic pancreatitis, Cystic fibrosis, Hemachromatosis, Trauma, Neoplasia

• Endocrinopathies• Acromegaly, Cushing syndrome, Hyperthyroidism, Pheochromocytoma

• Infections• CMV, Coxsackie B virus, Congenital rubella

• Drugs• Glucocorticoids, Thiazides, Thyroid hormone, Interferon-α, β adrenergic agonists, Protease inhibitors

• Genetic syndromes associated with diabetes• Down syndrome, Kleinfelter syndrome, Turner, syndrome, Prader-Willi syndrome

• Gestational diabetes mellitus

Page 9: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

ClassificationClassification• Type I Diabetes 5-10%

• Type II Diabetes 90-95%

• Genetic defects of Genetic defects of ββ cell function cell function• Maturity-onset diabetes of the young (MODY), Neonatal diabetesMaturity-onset diabetes of the young (MODY), Neonatal diabetes

• Genetic defects in insulin actionGenetic defects in insulin action

• Exocrine pancreatic defectsExocrine pancreatic defects• Chronic pancreatitis, Cystic fibrosis, Hemachromatosis, Trauma, NeoplasiaChronic pancreatitis, Cystic fibrosis, Hemachromatosis, Trauma, Neoplasia

• EndocrinopathiesEndocrinopathies• Acromegaly, Cushing syndrome, Hyperthyroidism, PheochromocytomaAcromegaly, Cushing syndrome, Hyperthyroidism, Pheochromocytoma

• InfectionsInfections• CMV, Coxsackie B virus, Congenital rubellaCMV, Coxsackie B virus, Congenital rubella

• DrugsDrugs• Glucocorticoids, Thiazides, Thyroid hormone, Interferon-Glucocorticoids, Thiazides, Thyroid hormone, Interferon-αα, , ββ adrenergic agonists, Protease inhibitors adrenergic agonists, Protease inhibitors

• Genetic syndromes associated with diabetesGenetic syndromes associated with diabetes• Down syndrome, Kleinfelter syndrome, Turner, syndrome, Prader-Willi syndromeDown syndrome, Kleinfelter syndrome, Turner, syndrome, Prader-Willi syndrome

• Gestational diabetes mellitusGestational diabetes mellitus

Page 10: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetes type I

• Chronic progressive autoimmune disorder

• 5-10% of all cases• Most common subtype in younger patients (<20 y.o.)

• Immune system reacts against endogenous β-cell antigens

Page 11: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetes type I

Immune cells

“absolute” insulin deficiency

pancreatic β-cell destruction

Failure of self tolerance in T-cells

Page 12: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Model of Diabetes type I

Adapted from N Rngl J Med 314:1360, 1986

Age (years)

Bet

a ce

ll m

ass

2510

Overt diabetes

Overt immunologic abnormalities

Normal insulin release

Progressive loss of insulin release

Glucose normal

? Precipitating event

Genetic predisposition

• HLA-DR3/DR4

• others

Environmental Factors

? Viral infections

(i.e. mumps, rubella, CMV)

(>90% β-cell destruction)

Page 13: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Type I pathology

Pathologic basis of disease – Robbins 8th

Insulitis (lymphoid cell infiltrate)

Page 14: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Insulitis (lymphoid cell infiltrate)

Type I pathology

Page 15: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetes type II

• 90-95% of all cases (most common type)• Adult onset – increasing in children

• No related to autoimmunity

• Multifactorial

-Genetic (i.e. genes associated with β-cell function / insulin secretion)

-Environmental

o Diet

o Sedentary life style

Obesity (i.e. adipokines, fatty acids, inflammation)

Page 16: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetes type II

2 metabolic defects:

• Insulin resistance

Failure of target tissues to respond normally to

insulin.

• β-cell dysfunction

Inadequate insulin secretion in states of insulin

resistance and hyperglycemia.

Page 17: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetes type II

pancreatic β-cell “preserved”

Hypersecretion of insulin

“relative” insulin deficiency

β-cell failure

Diabetes compensatory β-cell hyperfunction

Page 18: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Type II pathology

library.med.utah.edu

Amyloid replacement of islets

Page 19: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Amyloid

Fibrils that result from

abnormal folding of

proteins, which

become insoluble,

aggregate and deposit

in extracellular tissues

Page 20: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Congo Red stain

with polarization

Page 21: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Objectives• 3711-2 Describe the pathological changes in the pancreas for type I / II diabetes.

• 4619 Understand and recognize the pancreatic pathology in type I diabetes.

• 4620 4620 List, understand and recognize the pathology of the major List, understand and recognize the pathology of the major complications of diabetes: complications of diabetes: - Microvascular changes general aspects- Microvascular changes general aspects- Microvascular effects in retina- Microvascular effects in retina- Microvascular changes in nerves- Microvascular changes in nerves- Renal pathology- Renal pathology- Atherosclerosis in diabetes- Atherosclerosis in diabetes

• 4621 4621 Describe the special aspects of pathology of infection in diabetes.Describe the special aspects of pathology of infection in diabetes.

Page 22: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Objectives• 3711-2 3711-2 Describe the pathological changes in the pancreas for Describe the pathological changes in the pancreas for type Itype I / II diabetes / II diabetes..

• 4619 Understand and recognize the pancreatic pathology in type I 4619 Understand and recognize the pancreatic pathology in type I diabetes. diabetes.

• 4620 List, understand and recognize the pathology of the major complications of diabetes: - Microvascular changes general aspects- Microvascular effects in retina- Microvascular changes in nerves- Renal pathology- Atherosclerosis in diabetes

• 4621 4621 Describe the special aspects of pathology of infection in diabetes.Describe the special aspects of pathology of infection in diabetes.

Page 23: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

COMPLICATIONS OF DIABETES

Page 24: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Hyperglycemia is the primary initiating factor for damage of the target tissues

Nature 414:813-820, 2001

Dia

be

tic com

plica

tion

s(Advanced Glycation End products)

Page 25: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Complications of diabetes

• Macroangiopathy (medium and large sized arteries)

- Accelerated atherosclerosis

• Microangiopathy (small vessels)

- Retinopathy

- Nephropathy

- Neuropathy

Page 26: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Macrovascular diseaseAccelerated Atherosclerosis

Not specific, just worse

Page 27: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Atheromatous plaque

Pathologic basis of disease – Robbins 8th

Page 28: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Predisposition to atherosclerosis

• Increased risk of:

-Myocardial infarction (atherosclerosis of coronary arteries)

o Most common cause of death among diabetics

-Stroke

-Lower extremity gangrene

Persistent hyperglycemia/Insulin resistance on vascular compartment

Endothelial dysfunction

Page 29: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Ischemic peripheral vascular disease

Page 30: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Hyperglycemia

Glycosilation of BM proteins(AGE)

Thick and leaky blood vessels

Narrow lumen

Ischemic organ damage

Microvascular disease – general aspects

Page 31: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Ocular complications

• Glaucoma – increased two fold

• Cataracts – develop at earlier age

• Retinopathy

• Diabetes is the leading cause of blindness among 20-74yo

• Prevalence: ~70-80% diabetics with >10 years of disease

Page 32: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Thickened basement membrane

Normal

Ciliary body

Page 33: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetic retinopathy (DR)

• Progressive dysfunction of the retinal blood vessels caused by chronic hyperglycemia

• The best predictor of diabetic retinopathy is the duration of the disease

• After 20 years of diabetes, nearly 99% of patients with type 1 diabetes and 60% with type 2 have some degree of diabetic retinopathy

• Initially asymptomatic, if not treated though it can cause low vision and blindness

Page 34: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Diabetic retinopathy – 4 stages

• Non-proliferative DR

-Mild, moderate, severe

• Proliferative DR

Tim

e

Page 35: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Normal retina – Histology

Page 36: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Diabetic retinopathy - stages

• Non-proliferative DR

- Loss of pericytes and formation of microaneurysms

(most important - early characteristic manifestation)

NormalAntonetti et al NEJM 2012

DR

Page 37: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Loss of pericytes and microaneurysms

Page 38: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Diabetic retinopathy

• Non-proliferative DR

- Capillary leakage / Macular edema

- Hemorrhages and hard exudates

- Arteriolovenular shunts

Page 39: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Diabetic retinopathy

• Proliferative DR

- Neovascularization (up-regulation of VEGF)

- Vitreous hemorrhage

- Fibrovascular tissue proliferation – retinal detachment

Page 40: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetic retinopathy - fundoscopy

Page 41: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Page 42: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetic nephropathy

• Very important!

• Leading cause of end-stage renal disease

• Advance/end-stage kidney disease occurs in ~40% diabetics

• Renal failure: 2nd most common cause of death in diabetics

• Does not happen quickly: progression from microalbuminuria macroalbuminuria end-stage disease over 10-20 years

Page 43: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Normal glomerulus

Arterioles (afferent and efferent)

Tubules

Mesangial area

Page 44: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Tubular basement membrane thickening

Capillary basement membrane thickening

Diabetes

Page 45: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Electron microscopy

Glomerular basement membrane (GBM) thickening

Normal(~280-330 nm)

GBM

Page 46: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Nodular diabetic glomerulosclerosis

(Kimmelstiel-Wilson)

Tubular basement membrane thickening

Capillary basement membrane thickening

Page 47: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diffuse mesangial sclerosis

Page 48: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Silver stain

Microaneurysm formation

Page 49: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

PAS stain

Arteriolar hyalinosis (both afferent and

efferent)

Page 50: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Normal

Loss of podocytes

Page 51: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Pyelonephritis

Page 52: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Papillary necrosis

Page 53: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetic nephropathy – summary of findings

• Glomeruli

- Basement membrane thickening (earliest)

- Diffuse mesangial sclerosis

- Nodular glomerulosclerosis

- Microaneurysms

- Loss of podocytes

Page 54: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetic nephropathy – summary of findings

• Vessels- Arteriolar hyalinosis- Atherosclerosis (larger vessels)

• Tubulointerstitium- Tubular basement membrane thickening- Pyelonephritis- Papillary necrosis

• Final result: Scarring (fibrosis)

Decreased size

Page 55: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetic neuropathy

• Prevalence: ~50% of diabetics (80% if >15 years of disease)

• Time dependent

• Syndromes:

-Distal symmetric sensory(motor) polineuropathy-Autonomic neuropathy

(postural hypotension, incomplete bladder emptying: infections, sexual dysfunction)

-Focal/multifocal asymmetric neuropathy

(individual peripheral or cranial nerve: mononeuropathy; several individual nerves: mononeuropathy multiplex)

Page 56: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Distal symmetric sensorimotor neuropathyAxonal neuropathy

Thinly myelinated fibers

Segmental demyelination / Severe loss of myelinated fibers

Endoneurial arteriole wall

thickening

Normal

Page 57: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Enoch et al, University of Wales UK, 2004

Page 58: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Diabetic ulcers

• Painless• Surrounded by callus• At pressure points

Page 59: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Pathologic basis of disease – Robbins 8th

Page 60: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Objectives• 3711-2 3711-2 Describe the pathological changes in the pancreas for Describe the pathological changes in the pancreas for type Itype I / II diabetes / II diabetes..

• 4619 Understand and recognize the pancreatic pathology in type I 4619 Understand and recognize the pancreatic pathology in type I diabetes. diabetes.

• 4620 4620 List, understand and recognize the pathology of the major List, understand and recognize the pathology of the major complications of diabetes: complications of diabetes: - Microvascular changes general aspects- Microvascular changes general aspects- Microvascular effects in retina- Microvascular effects in retina- Microvascular changes in nerves- Microvascular changes in nerves- Renal pathology- Renal pathology- Atherosclerosis in diabetes- Atherosclerosis in diabetes

• 4621 Describe the special aspects of pathology of infection in diabetes.

Page 61: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Infections in diabetes

• More frequent, more serious

• Increase morbidity and mortality

• May be the first manifestation of the disease

• Precipitating factor for complications

(i.e. diabetic ketoacidosis, hypoglycemia)

Page 62: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Pathology of infection in diabetes

• Generalized impairment of immunity

-PMN and lymphocyte dysfunction: migration, phagocytosis and chemotaxis

-Complement deficiency

-Decreased cytokine response

-Glycation of Ig: decreased antibody function

• Non-immunologic anatomically specific factors

-Compromised local circulation – impaired wound healing

-Site specific changes

Page 63: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

Infections – Increased risk

• Lower extremity: Diabetic foot

- Contributors:

o Sensory neuropathy awareness of injury to the foot

o Motor neuropathy intrinsic muscles of the foot foot deformity

maldistribution of weight

o Autonomic neuropathy sweating dry and cracked skin

breaches in integrity of skin entry of microorganism

- Monomicrobial (Staphylococcus aureus/ epidermidis) or polymicrobial

- Bone (osteomyelitis) / articular involvement

- Often leads to amputation

Page 64: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Infections – Increased risk

• Head and neck

- Mucormycosis

o Rhinocerebral infection / Invasive pulmonary or GI

o Causative agent: Rhizopus, Mucor

- Malignant external otitis

o Extension to soft tissue, mastoid bone and CNS

o Causative agent: Pseudomonas aeruginosa

Page 65: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Mucormycosis

Page 66: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Infections – Increased risk

• Genitourinaryo Autonomic neuropathy incomplete bladder emptying urinary colonization by microorganisms

o High glucose concentration in urine growth of microorganisms

-Asymptomatic bacteriuria

-Bacterial pyelonephritis (E. coli, Proteus)

-Emphysematous pyelonephritis (E. coli, Enterobacter aerogenes)

-Emphysematous cystitis (E. coli, followed by Enterobacter, Proteus, Klebsiella, and Candida)

-Fungal cystitis (Candida)

-Perinephric abscess (E. coli, polymicrobial)

-Candida vulvovaginitis

Page 67: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Fungal cystitis - Candida

Page 68: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Infections – Increased risk

• Respiratory

-Streptococcus pneumoniae

-Influenza

-H1N1

-Tuberculosis

• Superficial fungal infections (oral candidiasis, onychomycosis, intertrigo)

• Emphysematous cholecystitis

• Necrotizing fasciitis

• Surgical wound infections

Vaccination

Page 69: Dr. Paula L. Blanco pblanco@toh.on.ca Pathology in Diabetes October 2015

[Unit name – Lecture title – Prof name]

Prevention for type 2 diabetes

• Canadian adults with diabetes are twice as likely to die prematurely, compared to people without diabetes.

• Life expectancy for people with type 1 diabetes may be shortened by as much as 15 years.

• Life expectancy for people with type 2 diabetes may be shortened by 5 to 10 years.

• Reduce risk by 58% by exercising ~20 min/d and losing 7% body weight.

Diabetes Prevention Program